Table 2.
Therapy and outcomes.
| COVID-19 ICU patients (n = 103) | Current treatment group (LMWH protocol) (n = 57) | |
|---|---|---|
| Therapy | ||
| Mean daily LMWH dose | ||
| Nadroparin (ml) | 1.00 ± 0.23 | 1.04 ± 0.24 |
| Nadroparin (IU) | 9500 ± 2185 | 9880 ± 2280 |
| Antiviral treatment | 6 (5.8%) | 5 (8.8%) |
| Antibiotic treatment | 95 (92.2%) | 50 (87.8%) |
| Antifungal treatment | 9 (8.7%) | 6 (10.5%) |
| CRRT | 18 (17.6%) | 4 (7.1%) |
| ECMO | 4 (7.0%) | 4 (3.9%) |
| Oxygen treatment | 101 (98.1%) | 55 (96.5%) |
| Vasopressors | 56 (54.3%) | 21 (38.9%) |
| Neuromuscular blockers | 47 (47.5%) | 16 (30.2%) |
| Prone position | 47 (46.1%) | 24 (42.9%) |
| Corticosteroids | 46 (44.7%) | 32 (56.1%) |
|
| ||
| Outcomes | ||
| Length of stay ICU | 8.47 ± 9.8 | 10.30 ± 1.53 |
| Length of stay hospital | 30.26 ± 24.3 | 30.78 ± 3.2 |
| GFR | 74.52 ± 28.59 | 75.61 ± 30.94 |
| Acute kidney failure | 45 (43.7%) | 16 (28.1%) |
| ICU mortality | 30 (29.1%) | 10 (17.5%) |
Results are displayed in mean ± SD or as numbers (%).